<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453608</url>
  </required_header>
  <id_info>
    <org_study_id>FER-CARS-05</org_study_id>
    <nct_id>NCT01453608</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency</brief_title>
  <acronym>CONFIRM-HF</acronym>
  <official_title>A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine, relative to placebo, the effect of iron repletion
      therapy using intravenous (IV) ferric carboxymaltose on exercise capacity in patients with
      chronic heart failure and iron deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in six minute walk test from baseline to week 24</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">304</enrollment>
  <condition>Iron Deficiency</condition>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ferinject (ferric carboxymaltose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject (ferric carboxymaltose)</intervention_name>
    <description>Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0</description>
    <arm_group_label>Ferinject (ferric carboxymaltose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline)</intervention_name>
    <description>Subjects will receive Placebo (saline) intravenously on Day 0</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Iron deficient subjects with stable chronic heart failure (CHF) (NYHA II-III) on
             optimal background therapy for CHF

          -  Reduced left ventricular ejection fraction

          -  Capable of completing 6 minute walk test

          -  At least 18 years of age and with written informed consent prior to any study specific
             procedures

        Exclusion Criteria:

          -  Erythropoietin stimulating agent (ESA) use, IV iron therapy and/or blood transfusion
             in previous 6 weeks prior to randomisation

          -  Exercise training program(s) in the 3 months prior to screening or planned in the next
             6 months

          -  Chronic liver disease and/or elevated liver enzymes

          -  Vitamin B12 and/or serum folate deficiency

          -  Subject is not using adequate contraceptive precautions during the study

          -  Body weight â‰¤ 35 kg

          -  No other significant cardiac or general disorders that would compromise the ability to
             give informed consent and/or comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Ponikowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Department - Centre for Heart Disease - Clinical Military Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Military Hospital</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-891</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higer Professional Education</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://eurheartj.oxfordjournals.org/content/early/2014/11/20/eurheartj.ehu385</url>
    <description>Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Confirm HF</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>October 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

